more

Novartis (NVS)

(Real Time Quote from BATS)

$118.62 USD

+0.12 (0.10%)

Updated Sep 4, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alnylam's Givlaari Gets Approval in Europe for Rare Disease

by Zacks Equity Research Published on March 04,2020

Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.

biotechs

The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics

by Zacks Equity Research Published on March 04,2020

The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics

medical

Roche's Esbriet Gets FDA Breakthrough Tag for New Indication

by Zacks Equity Research Published on March 03,2020

Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.

pharmaceuticals

Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

by Zacks Equity Research Published on March 03,2020

Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.

Top Analyst Reports for Merck, Novartis & Mondelez

by Mark Vickery Published on March 03,2020

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Novartis (NVS) and Mondelez International (MDLZ).

Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit

by Kinjel Shah Published on February 28,2020

FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.

pharmaceuticals

United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

by Zacks Equity Research Published on February 27,2020

United Therapeutics (UTHR) misses fourth-quarter estimates on both fronts. Stock declines in response.

Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Rise Y/Y

by Zacks Equity Research Published on February 27,2020

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2019.

pharmaceuticals

Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

by Kinjel Shah Published on February 21,2020

AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

pharmaceuticals

Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat

by Zacks Equity Research Published on February 21,2020

Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.

biotechs

Intellia (NTLA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research Published on February 20,2020

Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.

biotechs

Glaxo Underperforms Industry in a Year: What's in Store?

by Zacks Equity Research Published on February 18,2020

Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.

pharmaceuticals

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

by Zacks Equity Research Published on February 14,2020

AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

by Zacks Equity Research Published on February 14,2020

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales

by Zacks Equity Research Published on February 13,2020

Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.

Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study

by Zacks Equity Research Published on February 12,2020

Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.